QIAGEN completed the acquisition of an 80.1% stake in NeuMoDx Molecular for $248m.

QIAGEN, a provider of Sample to Insight solutions, completed the acquisition of an 80.1% stake in NeuMoDx Molecular, a diagnostics instruments company, from private equity firms Baird Capital Partners, Venture Investors, Arboretum Ventures and Pfizer Venture for $248m. “NeuMoDx’s automated molecular testing platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics assays, including laboratory-developed tests. NeuMoDx has built an unparalleled platform that has demonstrated superior value during the coronavirus pandemic. This will expand QIAGEN’s portfolio of automated testing solutions and provide another driver for future growth,” Thierry Bernard, QIAGEN CEO.